TD-1211 Demonstrates Constipation-relieving Effects, Including Decrease in Rescue Laxative Use, in Patients with Opioid-Induced Constipation: 2011 ACG Presidential Poster

Vickery, Ross G.; Li, Yuping; Köhler, R; Webster, Lynn R.; Singla, Neil; Daniëls, O.

doi:10.14309/00000434-201110002-01341

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase IIb study of TD-1211 (10 mg and 15 mg) showed increased numbers of CSBMs and SBMs during the 5-week treatment period [Vickery et al 2013]. TD-1211 dose dependently accelerated time to first SBM [Vickery et al 2011].Treatment related gastrointestinal adverse effects were mild and resolved within a few days of starting treatment. There were no treatment related serious adverse effects.…”

Section: Drugs In Development and Future Targets (Table 3)mentioning

confidence: 99%

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities

Nelson

Camilleri

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

With the recent introduction and approval of medications directed at the treatment of opioid induced constipation (OIC) in patients with nonmalignant pain, there is increased interest and understanding of the unmet need and opportunities to enhance patient management. The high incidence of OIC is associated with rapid increase of narcotic analgesic prescriptions for nonmalignant chronic pain. This review addresses briefly the mechanisms of action of opioids that lead to OIC, the differential tolerance of gastrointestinal organs to the effects of opioids, the size and scope of the problem, the definition and outcome measures for OIC, current differential diagnosis and management algorithms, and the pharmacology and efficacy of treatments for OIC in patients with nonmalignant pain.

show abstract

Section: Drugs In Development and Future Targets (Table 3)mentioning

confidence: 99%

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities

Nelson

Camilleri

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…A total of 7849 participants were included in the 31 RCTs. [14][15][16] Of these RCTs, seven [14][15][16]19,20,30 used naldemedine (n = 1399), seven 18,23,24,27,29,34,35 used methylnaltrexone (n = 605), four 21,28,31,32 used alvimopan (n = 518), six 22,33,40 used naloxegol (n = 547), five 25,36-38 used bevenopran (n = 776), and two 26,39 used axelopran (n = 69). All 29 RCTs gave a placebo to the control group (n = 3935).…”

Section: Resultsmentioning

confidence: 99%

“…36,37 Change from baseline of spontaneous bowel movements. A total of 20 RCTs [14][15][16][20][21][22]25,26,[28][29][30][31][32][33][34]39 with 5622 patients were included in the analysis of change from baseline of SBM per week. The overall results showed a significant increase in this change among participants treated with PAMORA (MD, 1.43; 95% CI, 1.18-1.68; P < 0.00001; Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Proportion of responders. In total, 21 RCTs [14][15][16]18,20,21,23,24,[26][27][28][29][31][32][33][34][35]39,40 of PAMORA recruited 4821 patients. PAMORA showed a greater response than placebo (RR, 1.81; 95% CI, 1.55-2.12; P < 0.00001).…”

Section: Resultsmentioning

confidence: 99%

“…We retrieved the full texts of the remaining 132 articles. Ultimately, 51 articles, including 31 RCTs, met our inclusion criteria . Figure shows the screening process and reasons for excluding studies.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Peripherally acting μ‐opioid antagonist for the treatment of opioid‐induced constipation: Systematic review and meta‐analysis

Nishie

Yamamoto

Yamaga³

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Opioid‐induced constipation (OIC) is a frequent adverse event (AE) that impairs patients' quality of life (QOL). Peripherally acting μ‐opioid receptor antagonists (PAMORAs) have been recognized as a treatment option for OIC, but the effect consistent across the studies has not been evaluated. Methods We conducted a quantitative meta‐analysis to explore the efficacy of PAMORA for OIC (registered with PROSPERO: CRD42018085298). We systematically searched randomized controlled trials (RCTs) in Medline, Embase, and Central databases. Change from baseline in spontaneous bowel movements, pooled proportion of responders, QOL, and AEs were calculated and compared with results in placebo cases. Results We included 31 RCTs with 7849 patients. A meta‐analysis revealed that patients under PAMORA therapy had considerably improved spontaneous bowel movement from baseline compared with those given placebo (20 RCTs; mean difference, 1.43; 95% confidence interval [CI], 1.18–1.68; n = 5622) and more responded (21 RCTs; risk ratio [RR], 1.81; 95% CI, 1.55–2.12; n = 4821). Moreover, QOL of patients receiving PAMORA was significantly better (8 RCTs; mean difference, −0.22; 95% CI, −0.28 to −0.17; n = 2884). AEs were increased significantly in the PAMORA group (26 RCTs; RR, 1.10; 95% CI, 1.06–1.15; n = 7715), especially in gastrointestinal disorders, whereas serious AEs were not significant (17 RCTs; RR, 1.04; 95% CI, 0.85–1.28; n = 5890). Conclusion Peripherally acting μ‐opioid receptor antagonist has been shown to be effective and durable for patients with OIC and is the only drug with confirmed evidence in meta‐analysis. The possibility of publication bias was the limitation of this study.

show abstract

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Camilleri¹

2013

J. Clin. Invest.

View full text Add to dashboard Cite

Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. IntroductionGastrointestinal motility and functional disorders result in either abnormal propulsion of content or excessive sensation of normal or abnormal functions in different regions of the gut. These conditions constitute about 40% of referrals to gastroenterologists, and they result in significant disease burden. Advances in clinical management of these disorders are based on understanding the basic mechanisms involved in sensorimotor and secretory functions, coupled with clinical investigation and trial methodology.The most frequent gastrointestinal motility and functional disorders are esophagitis, gastroparesis, chronic diarrhea, chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and visceral pain. This review summarizes the pathophysiology, lists commonly used current medications, and focuses on pharmacological agents in development for each disorder. At present, several approved medications relieve constipation and diarrhea; the major unmet needs are in gastroparesis, OIC, and visceral pain.

show abstract

TD-1211 Demonstrates Constipation-relieving Effects, Including Decrease in Rescue Laxative Use, in Patients with Opioid-Induced Constipation: 2011 ACG Presidential Poster

Cited by 4 publications

References 0 publications

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities

Peripherally acting μ‐opioid antagonist for the treatment of opioid‐induced constipation: Systematic review and meta‐analysis

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Contact Info

Product

Resources

About